Otic Glucocorticoids

Otic agents

Fluocinolone

• Corticosteroids inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary and fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation

• Mechanism of ocular effects is unknown. Corticosteroids may induce phospholipase A2 inhibitory proteins; these proteins may inhibit release of arachidonic acid, thus controlling biosynthesis of potent mediators of inflammation (e.g., prostaglandins, leukotrienes)

Management of chronic noninfectious uveitis affecting the posterior segment of the eye

• Viral diseases of the cornea and conjunctiva (e.g., epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, varicella)

• Mycobacterial infection of the eye

• Fungal diseases of ocular structures

• Known or suspected hypersensitivity to fluocinolone acetonide, other corticosteroids, or any ingredient in the formulation

• Cataracts, increased IOP, ocular pain, and surgical complications

• Reduced visual acuity, conjunctival hemorrhage or hyperemia, glaucoma, blurred vision, abnormal sensation in the eye, ocular irritation or inflammation, hypotony, pruritus, vitreous floaters or hemorrhage, ptosis, maculopathy, eyelid edema, increased tearing, and dry eye

• Headache